公开(公告)号：US20250019703A1

公开(公告)日：2025-01-16

申请号：US18711961

申请日：2022-07-15

Applicant: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Dongjun LEE ,  Jayoung KIM

IPC: C12N15/113 ,  A61K31/337 ,  A61K31/7072 ,  A61P35/02

Abstract: One aspect relates to a pharmaceutical composition for the prevention or treatment of blood cancer, comprising a surfeit locus protein 4 (SURF4) inhibitor. The composition according to one aspect inhibits SURF4 to increase the expression of pJNK and decrease the expression of pERK and pAKT, and thus apoptosis of blood cancer cells is increased, thereby exhibiting an effect of preventing or treating blood cancers. In addition, by administering the composition according to one aspect together with an existing anticancer agent, a synergistic effect showing more significant apoptosis than when an existing anticancer agent was administered was confirmed, which can contribute to the blood cancer treatment market/industry.

公开(公告)号：US20240398833A1

公开(公告)日：2024-12-05

申请号：US18699698

申请日：2022-09-19

Applicant: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Inventor： Dongjun LEE ,  Soo Yeon WOO

IPC: A61K31/575 ,  A23K20/168 ,  A61K8/63 ,  A61P35/02 ,  A61Q19/00

Abstract: The present invention relates to a pharmaceutical composition, containing 27-hydroxycholesterol, for preventing or treating myeloid leukemia, and more specifically, to a pharmaceutical composition which suppresses the proliferation of hematopoietic stem cells by increasing the active oxygen of the hematopoietic stem cells and activating a cascade of endoplasmic reticulum stress, and promotes the apoptosis of blood cancer cells by activating the IRE1a, eIF2a, and CHOP signaling pathways which are important for the apoptosis of blood cancer cells.